Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to Internal Medicine Unit.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
11
2021
accepted:
29
04
2022
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
During COVID-19 pandemic, Internal Medicine Units (IMUs) accounted for about 70% of patients hospitalized. Although a large body of data has been published regarding the so-called first wave of the pandemic, little is known about the characteristics and predictors of worse outcomes of patients managed in IMUs during the second wave. We prospectively assessed demographics, comorbidities, treatment and outcomes, including ventilation support (VS) and death, in patients admitted to our IMU for SARS-CoV-2 between October 13th, 2020 and January 21st, 2021. Clinical evolution and biochemical testing 1, 7 and 14 days after COVID-19 diagnosis were recorded. We studied 120 patients (M/F 56/64, age 71±14.5 years) admitted to our IMU. Most of them had at least one comorbidity (80%). Patients who died were older, more frequently underweight, affected by malignant neoplasms and on statin therapy compared to patients eventually discharged. Both worse outcome groups (VS and death) presented higher neutrophils, ferritin, IL-6 and lower total proteins levels than controls. Age was significantly associated with mortality but not with VS need. The multivariate analysis showed age and gender independent association of mortality with underweight, malignancy and antibiotics use at the admission. With regard to biochemical parameters, both unfavourable outcomes were positively associated with high WBC count, neutrophils, blood urea nitrogen and low serum total proteins. Our study identified inflammation, underweight, malignancy and a marked catabolic state as the main predictors for worse outcomes in COVID-19 patients admitted to IMU during the so-called second wave of the pandemic.
Identifiants
pubmed: 35584141
doi: 10.1371/journal.pone.0268432
pii: PONE-D-21-35509
pmc: PMC9116641
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268432Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
PLoS One. 2018 Jan 25;13(1):e0191697
pubmed: 29370259
Intern Emerg Med. 2021 Jun;16(4):1005-1015
pubmed: 33893976
Int J Antimicrob Agents. 2020 Sep;56(3):106110
pubmed: 32712332
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Obes Rev. 2020 Oct;21(10):e13095
pubmed: 32686331
Intern Emerg Med. 2021 Jun;16(4):989-996
pubmed: 33620680
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359
pubmed: 33932335
Int J Med Sci. 2021 Jan 21;18(6):1356-1362
pubmed: 33628091
Allergy. 2021 Feb;76(2):533-550
pubmed: 32662525
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Kidney Med. 2021 Jan-Feb;3(1):60-63.e1
pubmed: 33283182
Arch Pathol Lab Med. 2020 Dec 1;144(12):1457-1464
pubmed: 32649222
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Obesity (Silver Spring). 2021 Feb;29(2):279-284
pubmed: 33128848
Eur J Clin Invest. 2020 Jun;50(6):e13250
pubmed: 32367527
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Blood Rev. 2009 May;23(3):95-104
pubmed: 18835072
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Lancet. 2020 Mar 14;395(10227):e49-e50
pubmed: 32119824
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
EMBO Mol Med. 2020 Jul 7;12(7):e12421
pubmed: 32428990
Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-755
pubmed: 33549450
Diagn Pathol. 2021 Apr 13;16(1):31
pubmed: 33849598
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
BMJ. 2020 Feb 28;368:bmj.m799
pubmed: 32111645
Allergy. 2020 Jul;75(7):1813-1815
pubmed: 32306406